Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYTH3 | O43739 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | EPN1 | Q9Y6I3 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 8/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | STING1 | Q86WV6 | 6/20 | 0.36 |
| ▸ | PYGL | P06737 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ASPH | Q12797 | 1/20 | 0.36 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3822963 | 0.85 | PYGL (0.50) | PYGLNPC1RAB9A | |
| SCHEMBL3825349 | 0.84 | HCAR2 (0.44) | CYTH3BTKEPN1HCAR2DAO | |
| SCHEMBL5013483 | 0.81 | GPR27 (0.44) | CYTH3BTKEPN1HCAR2DAO | |
| SCHEMBL5009899 | 0.81 | STING1 (0.41) | HCAR2DAOSTING1PYGLKDM4E | |
| SCHEMBL5013495 | 0.80 | PYGL (0.44) | PYGLNPC1RAB9A | |
| SCHEMBL5012235 | 0.80 | KEAP1 (0.59) | CYTH3BTKEPN1HCAR2DAO | |
| SCHEMBL5008542 | 0.78 | MEN1 (0.40) | HCAR2DAOSTING1KDM4EHCAR3 | |
| SCHEMBL14587862 | 0.75 | HTT (0.48) | KDM4ERAB9A | |
| Imidazole SCHEMBL3820589 | 0.75 | PYGL (0.42) | PYGLNPC1RAB9A | |
| SCHEMBL14587833 | 0.74 | PTGES (0.40) | PYGLNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | CYTH3 3210/4885BTK 2283/4885EPN1 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.